NuMedii

Thomson Reuters and NuMedii this week announced a partnership that will pair NuMedii's underlying informatics technology with curated drug and disease information and systems biology expertise from Thomson Reuters for use in identifying new applications for existing drugs.

Atul Butte, an associate professor in Stanford University's School of Medicine, was recently named as one of 13 Open Science Champions of Change by the White House's Office of Science and Technology Policy for his efforts to use and support open data in biomedical research.

NuMedii said this week that it will use its predictive platform to identify potential therapeutic candidates for gastrointestinal disorders and cystic fibrosis for Aptalis Pharma.

By Uduak Grace Thomas
NuMedii, a Stanford University spinoff, hopes to make its bread and butter by partnering with traditional and specialty pharmaceutical companies to identify new indications for existing medicines.

Originally published August 22.
By Turna Ray